PfDHODH-IN-1 is primarily used in research focused on targeting the Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) enzyme, which is crucial for the survival of the malaria parasite. By inhibiting this enzyme, it disrupts the pyrimidine biosynthesis pathway, effectively halting the parasite's ability to replicate and proliferate. This makes it a promising candidate for the development of antimalarial drugs. Researchers are particularly interested in its potential to combat drug-resistant strains of malaria, offering a new avenue for therapeutic intervention. Its application extends to preclinical studies where it is evaluated for efficacy, safety, and pharmacokinetics to determine its suitability for further drug development.